P
Pengwu Zheng
Researcher at Jiangxi Science and Technology Normal University
Publications - 78
Citations - 760
Pengwu Zheng is an academic researcher from Jiangxi Science and Technology Normal University. The author has contributed to research in topics: Moiety & Ring (chemistry). The author has an hindex of 14, co-authored 78 publications receiving 501 citations.
Papers
More filters
Journal ArticleDOI
Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold
TL;DR: Structural-activity relationships (SARs) and docking studies indicated that the pyrazole scaffolds exerted key effect on antitumor activities of target compounds.
Journal ArticleDOI
Synthesis and anticancer activity of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives bearing chromone moiety.
Chengyu Sun,Chen Chen,Shan Xu,Jianqiang Wang,Yan Zhu,Dejia Kong,Hong Tao,Mengjia Jin,Pengwu Zheng,Wufu Zhu +9 more
TL;DR: The results indicated that the optimized compound 10j showed excellent inhibitory activity and cytotoxicity against mTOR kinase, PI3Kα kinase and five cancer cell lines with IC50 values of 1.1μM, 0.92μM and 8.3μM.
Journal ArticleDOI
Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors
Qidong Tang,Qidong Tang,Linxiao Wang,Yayi Tu,Wufu Zhu,Rong Luo,Qidong Tu,Ping Wang,Chunjiang Wu,Ping Gong,Pengwu Zheng +10 more
TL;DR: A series of pyrrolo[2,3-b]pyridine derivatives bearing 1,2, 3-triazole moiety were designed, synthesized, and evaluated for their c-Met kinase inhibitory activities and antiproliferative activities against 4 cancer cell lines (HT-29, A549, MCF-7, and PC-3) in vitro as discussed by the authors.
Journal ArticleDOI
The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation
TL;DR: The recent advances in medicinal chemistry of fourth-generation EGFR-TKIs are discussed, as well as further discussed the clinical challenges and future prospects of treating patients with EGFR mutations resistant to third-generationEGFR- TKIs.
Journal ArticleDOI
Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Wufu Zhu,Wenhui Wang,Shan Xu,Jianqiang Wang,Qidong Tang,Chunjiang Wu,Yanfang Zhao,Pengwu Zheng +7 more
TL;DR: Four series of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety were designed, synthesized and evaluated for the IC50 values against three cancer cell lines, and the most promising compound 15e showed superior activity to Foretinib.